Emerald (NYSE:EEX – Get Free Report) and Augmedix (OTCMKTS:AUGX – Get Free Report) are both small-cap consumer discretionary companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.
Institutional & Insider Ownership
12.9% of Emerald shares are owned by institutional investors. Comparatively, 71.6% of Augmedix shares are owned by institutional investors. 3.5% of Emerald shares are owned by company insiders. Comparatively, 11.0% of Augmedix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Volatility & Risk
Emerald has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500. Comparatively, Augmedix has a beta of -0.4, indicating that its share price is 140% less volatile than the S&P 500.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares Emerald and Augmedix’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Emerald||$325.90 million||0.81||$130.80 million||$0.14||30.00|
|Augmedix||$37.02 million||5.69||-$24.45 million||($0.56)||-9.21|
Emerald has higher revenue and earnings than Augmedix. Augmedix is trading at a lower price-to-earnings ratio than Emerald, indicating that it is currently the more affordable of the two stocks.
This is a summary of current ratings and target prices for Emerald and Augmedix, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Emerald currently has a consensus target price of $9.60, suggesting a potential upside of 128.57%. Augmedix has a consensus target price of $6.83, suggesting a potential upside of 32.43%. Given Emerald’s higher probable upside, analysts clearly believe Emerald is more favorable than Augmedix.
Emerald beats Augmedix on 9 of the 13 factors compared between the two stocks.
Emerald Holding, Inc. operates business-to-business (B2B) trade shows in the United States. It operates in two segments, Commerce; and Design, Creative and Technology. The Commerce segment engages in the events and services covering merchandising, licensing, retail sourcing, and marketing that enables professionals to make informed decisions and meet consumer demands. The Design, Creative and Technology segment provides events and services that support various industries connecting businesses and professionals with products, operational strategies, and integration to drive new business and streamline processes, and creative solutions. It also operates content and content-marketing websites, and related digital products, as well as produce publications. In addition, the company operates Elastic Suite platform that streamlines the wholesale buying process for brands and retail buyers; and Flex platform. Emerald Holding, Inc. was incorporated in 2013 and is based in New York, New York.
Augmedix, Inc. provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Notes that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, a self-service mobile software application. The company enables clinicians to access its applications through mobile devices, such as smartphones or Google Glass. It serves health systems and specialty groups. The company was founded in 2013 and is headquartered in San Francisco, California.
Receive News & Ratings for Emerald Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emerald and related companies with MarketBeat.com's FREE daily email newsletter.